News
Clinical Trials Arena on MSN7d
Gilead reports final outcomes from trial of bulevirtide for chronic HDVThe trial is aimed at assessing long-term efficacy as well as safety of the therapy in 150 chronic HDV patients.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback